Femasys stock.

The latest price target for . Femasys (NASDAQ: FEMY) was reported by HC Wainwright & Co. on November 14, 2023.The analyst firm set a price target for $10.00 expecting FEMY to rise to within 12 ... 0.13% QQQ 389.08 0.11% SPIKE – 3.39% BTC/USD 37034.02 0.9542% DIA 353.48 0.09% 187.02 0.81% TLT 91.10 1.45% Femasys Inc (NASDAQ:FEMY) $1.04 …WebNov 28, 2023 · Femasys, a medical device company, is set to launch its minimally invasive reproductive health products for women in 2024. ... Its stock ran from $0.33 to an intraday high of $4.75 a few days ... Dec 2, 2023 · Femasys Inc (NASDAQ:FEMY) trade information. Femasys Inc (FEMY) registered a -2.33% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.33% in intraday trading to $0.93 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -9.71%, and it has moved by -33.09% in ...

Dec 31, 2022 · Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Contacts: Investors Chuck Padala LifeSci Advisors, LLC +1-917-741-7792 [email protected]. Femasys Inc. Investor Contact: [email protected]. Media Contact ...

Femasys Inc () Stock Market info Recommendations: Buy or sell Femasys stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Femasys share forecasts, stock quote and buy / sell signals below.According to present data Femasys's FEMY shares and potentially its market environment have been in bearish …

Operating Status Active. Last Funding Type Post-IPO Debt. Legal Name Femasys Inc. Stock Symbol NASDAQ:FEMY. Company Type For Profit. Contact Email [email protected]. Phone Number 1 (770) 500-3910. Femasys is a biomedical company focused on transforming women’s healthcare worldwide by …Since then, however, the stock has slipped by 47%. Writing on Femasys for Chardan Research, 5-star analyst Keay Nakae takes care to laud “the potential of its next generation products addressing ...Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.Apr 19, 2023 · In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions. The Zacks Consensus Estimate for Femasys’ sales in the third quarter of 2023 is pegged at $0.4 million. However, sales in the United States declined year over year in the second quarter of 2023 ...

Femasys Inc stock performance at a glance. Check Femasys Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.

Femasys Inc (NASDAQ:FEMY) trade information. Femasys Inc (FEMY) registered a -2.33% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.33% in intraday trading to $0.93 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -9.71%, and it has moved …

ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include ...Stock Price Targets. High, $12.00. Median, $8.50. Low, $5.00. Average, $8.50. Current Price, $0.9522. Yearly Numbers. Estimates. FEMY will report 2023 earnings ...Oct 2, 2023 · Femasys Inc, a medical technology company, has been attracting attention from investors due to its positive stock performance on October 2, 2023. According to data from CNN Money, the company has received favorable price forecasts from four analysts, with a median target of $8.50. The high estimate is $13.00, while the low estimate is $5.00. Find the latest Femasys Inc. (FEMY) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...3 equities research analysts have issued twelve-month price targets for Femasys' shares. Their FEMY share price targets range from $7.00 to $10.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 884.9% from the stock's current price. View analysts price targets for FEMY or ...

Nov 30, 2023 · ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ... ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide …WebThe stock of Femasys Inc (FEMY) has seen a -20.00% decrease in the past week, with a -27.78% drop in the past month, and a 152.43% flourish in the past quarter. The volatility ratio for the week is 12.52%, and the volatility levels for the past 30 days are at 13.78% for FEMY. The simple […]Find the latest SEC Filings data for Femasys Inc. Common Stock (FEMY) at Nasdaq.com.52 Wk Low 0.25 52 Wk High 4.75 Avg. Volume 1,640,879 Market Cap 22.30 M Dividend 0.00 ( 0.00%) Beta NA Key Earnings Data Earnings ESP 0.00%WebPharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (Femasys), a biomedical company focused on meeting... Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update Globe Newswire • …

These promising developments of Femasys’s products further solidify the Buy rating. In another report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $10.00 price ...

Femasys Inc. FEMYNASDAQ FEMYNASDAQ 0.9138USD +0.0118 +1.31% At close at 16:59 UTC-8 See on Supercharts Overview News Ideas Financials Technicals Forecast …WebFemasys ( NASDAQ: FEMY) shares jumped 21% midday Monday following news that the US Food and Drug Administration has approved its investigational device exemption application to begin clinical ...FEMY | Complete Femasys Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Wall Street’s analysts know that buying low is part of a winning stock strategy, and they’ve been looking for stocks that are low – undervalued, and possibly hitting bottom. It’s the first step in an old formula for success, with the next, of course, being to sell high. Some recent picks from the analyst corps, pulled up via the TipRanks platform, may raise …Femasys expects the resulting patent, when issued, will have an anticipated expiration in 2039, at the earliest. In October, Femasys regained compliance with Nasdaq’s minimum bid price requirement, after having received a notice on June 1, 2023 from Nasdaq that they were not in compliance with such requirement.Description. Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient ... Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional …Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in permanent birth control and front-end infertility.

Femasys, a medical device company, is set to launch its minimally invasive reproductive health products for women in 2024. ... Its stock ran from $0.33 to an intraday high of $4.75 a few days ...

Historical Stock Quote. Investment Calculator. Amount ($) Start Date: End Date: Compare to: S&P 500. Nasdaq 100. Dow 30. Other. Reinvest Dividends. Calculate Investment. ... At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party.

Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.The Zacks Consensus Estimate for Femasys’ sales in the third quarter of 2023 is pegged at $0.4 million. However, sales in the United States declined year over year in the second quarter of 2023 ...FEMY - Femasys Inc Stock Price and Quote Nov-23-23 03:38PM 20 Countries with the Highest Teenage Pregnancy Rates (Insider Monkey) Nov-15-23 08:30AM PharmaCyte …WebFemasys Stock Earnings. The value each FEMY share was expected to gain vs. the value that each FEMY share actually gained. Femasys ( FEMY) reported Q3 2023 earnings per share (EPS) of -$0.26, missing estimates of -$0.22 by 21.75%. In the same quarter last year, Femasys 's earnings per share (EPS) was -$0.25. Femasys is expected to release next ...Femasys has received 510 (k) Clearance from the FDA for FemaSeed®, an innovative infertility treatment. The clearance allows for the U.S. commercialization of FemaSeed®, which delivers sperm directly to the fallopian tube. FemaSeed® is expected to reduce procedural complications compared to other treatments.Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Femasys Inc (FEMY) stock is trading at $1.10 as of 10:08 AM on Wednesday, Nov 15, an increase of $0.17, or 18.28% from the previous closing price of $0.93. The stock has traded between $1.05 and $1.25 so far today. Volume today is 2,748,419 compared to average volume of 3,456,068.Get the latest Femasys Inc. (FEMY) stock news and headlines to help you in your trading and investing decisions.Web

Femasys-stock; News for Femasys Femasys; ... warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.18 per share expiring one year from issuance and ...Stock Info Stock Quote Price $1.03 Volume 3,368,658 Change +0.12 % Change +12.72% Today's Open $0.96 Previous Close $0.91 Intraday High $1.14 Intraday …WebFemasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.Instagram:https://instagram. stratasys stock priceinteractive brokers options paper tradingtmus share pricevteb yield On average, Wall Street analysts predict. that Femasys's share price could reach $9.00 by Nov 14, 2024. The average Femasys stock price prediction forecasts a potential upside of 821.19% from the current FEMY share price of $0.98. best stablecoinsrumble sock Femasys (FEMY) shares fell 13% premarket on Wednesday after the biomedical company announced an offering to raise $3.9M.The company is selling 3,196,722 shares of common stock (or... economic collapse china Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical OfficerWebSee the latest Femasys Inc stock price (FEMY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.